Lipocine Inc

LPCN

Company Profile

  • Business description

    Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

  • Contact

    675 Arapeen Drive
    Suite 202
    Salt Lake CityUT84108
    USA

    T: +1 801 994-7383

    E: [email protected]

    https://www.lipocine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    14

Stocks News & Analysis

stocks

AI lands a blow on some Aussie stocks – yet stands to benefit others

AI is reshaping ASX tech moats - but some are more insulated than others.
stocks

This might be the best core stock bargain in the US market today

Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks

Data center demand drives strong earnings outlook for SGM

Sims guides huge earnings upgrade as data center metals demand spikes.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,552.6077.000.91%
CAC 407,801.77136.151.78%
DAX 4022,875.96495.772.22%
Dow JONES (US)46,464.47887.001.95%
FTSE 1009,974.4556.120.57%
HKSE24,382.47894.85-3.54%
NASDAQ22,037.28389.671.80%
Nikkei 22551,515.491,857.04-3.48%
NZX 50 Index12,899.7290.27-0.69%
S&P 5006,613.26106.781.64%
S&P/ASX 2008,365.9082.400.99%
SSE Composite Index3,813.28143.77-3.63%

Market Movers